Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Change in Cash: 2009-2024

Historic Change in Cash for Ligand Pharmaceuticals (LGND) over the last 16 years, with Dec 2024 value amounting to $49.4 million.

  • Ligand Pharmaceuticals' Change in Cash rose 57.67% to $71.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $75.8 million, marking a year-over-year increase of 73.12%. This contributed to the annual value of $49.4 million for FY2024, which is 323.80% up from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Change in Cash stood at $49.4 million for FY2024, which was up 323.80% from -$22.1 million recorded in FY2023.
  • Ligand Pharmaceuticals' 5-year Change in Cash high stood at $49.4 million for FY2024, and its period low was -$28.4 million during FY2021.
  • In the last 3 years, Ligand Pharmaceuticals' Change in Cash had a median value of $25.5 million in 2022 and averaged $17.6 million.
  • Its Change in Cash has fluctuated over the past 5 years, first slumped by 186.53% in 2023, then surged by 323.80% in 2024.
  • Ligand Pharmaceuticals' Change in Cash (Yearly) stood at -$24.3 million in 2020, then fell by 16.98% to -$28.4 million in 2021, then surged by 189.61% to $25.5 million in 2022, then crashed by 186.53% to -$22.1 million in 2023, then surged by 323.80% to $49.4 million in 2024.